A Detailed Analysis of the General Anesthesia Drugs Market: Poised for Robust Growth Driven by Increasing Surgical Procedures, Advancements in Drug Formulations, and Rising Healthcare Infrastructure Worldwide
Report ID: PMRREP33865
Number of Pages: 210
Format: PPT*, PDF, EXCEL
Industry: Healthcare
Published Date: January-2024
1. Executive Summary
1.1. Global General Anesthesia Drugs Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Drug Class Lifecycle Analysis
2.4. General Anesthesia Drugs Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Applications
2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape
3. Global General Anesthesia Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2013-2016
3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global General Anesthesia Drugs Market Outlook: Drug Class
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug Class, 2018 - 2022
3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
3.3.3.1. Propofol
3.3.3.2. Sevoflurane
3.3.3.3. Dexmedetomidine
3.3.3.4. Desflurane
3.3.3.5. Remifentanil
3.3.3.6. Midazolam
3.3.3.7. Others
3.4. Market Attractiveness Analysis: Drug Class
3.5. Global General Anesthesia Drugs Market Outlook: Route of Administration
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Route of Administration, 2018 - 2022
3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
3.5.3.1. Intravenous Anesthesia
3.5.3.2. Inhaled Anesthesia
3.6. Market Attractiveness Analysis: Route of Administration
3.7. Global General Anesthesia Drugs Market Outlook: End-User
3.7.1. Introduction / Key Findings
3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By End-User, 2018 - 2022
3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
3.7.3.1. Hospitals
3.7.3.2. Ambulatory surgical centers
3.7.3.3. Specialty clinics
3.8. Market Attractiveness Analysis: End-User
4. Global General Anesthesia Drugs Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia and Oceania
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America General Anesthesia Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
5.3.1. By Country
5.3.2. By Drug Class
5.3.3. By Route of Administration
5.3.4. By End-User
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
5.5.1. Propofol
5.5.2. Sevoflurane
5.5.3. Dexmedetomidine
5.5.4. Desflurane
5.5.5. Remifentanil
5.5.6. Midazolam
5.5.7. Others
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
5.6.1. Intravenous Anesthesia
5.6.2. Inhaled Anesthesia
5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
5.7.1. Hospitals
5.7.2. Ambulatory surgical centers
5.7.3. Specialty clinics
5.8. Market Attractiveness Analysis
6. Europe General Anesthesia Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Drug Class
6.3.3. By Route of Administration
6.3.4. By End-User
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Türkiye
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
6.5.1. Propofol
6.5.2. Sevoflurane
6.5.3. Dexmedetomidine
6.5.4. Desflurane
6.5.5. Remifentanil
6.5.6. Midazolam
6.5.7. Others
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
6.6.1. Intravenous Anesthesia
6.6.2. Inhaled Anesthesia
6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
6.7.1. Hospitals
6.7.2. Ambulatory surgical centers
6.7.3. Specialty clinics
6.8. Market Attractiveness Analysis
7. East Asia General Anesthesia Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Drug Class
7.3.3. By Route of Administration
7.3.4. By End-User
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
7.5.1. Propofol
7.5.2. Sevoflurane
7.5.3. Dexmedetomidine
7.5.4. Desflurane
7.5.5. Remifentanil
7.5.6. Midazolam
7.5.7. Others
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
7.6.1. Intravenous Anesthesia
7.6.2. Inhaled Anesthesia
7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
7.7.1. Hospitals
7.7.2. Ambulatory surgical centers
7.7.3. Specialty clinics
7.8. Market Attractiveness Analysis
8. South Asia & Oceania General Anesthesia Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Route of Administration
8.3.4. By End-User
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
8.5.1. Propofol
8.5.2. Sevoflurane
8.5.3. Dexmedetomidine
8.5.4. Desflurane
8.5.5. Remifentanil
8.5.6. Midazolam
8.5.7. Others
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
8.6.1. Intravenous Anesthesia
8.6.2. Inhaled Anesthesia
8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
8.7.1. Hospitals
8.7.2. Ambulatory surgical centers
8.7.3. Specialty clinics
8.8. Market Attractiveness Analysis
9. Latin America General Anesthesia Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By End-User
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
9.5.1. Propofol
9.5.2. Sevoflurane
9.5.3. Dexmedetomidine
9.5.4. Desflurane
9.5.5. Remifentanil
9.5.6. Midazolam
9.5.7. Others
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
9.6.1. Intravenous Anesthesia
9.6.2. Inhaled Anesthesia
9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
9.7.1. Hospitals
9.7.2. Ambulatory surgical centers
9.7.3. Specialty clinics
9.8. Market Attractiveness Analysis
10. Middle East & Africa General Anesthesia Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By End-User
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
10.5.1. Propofol
10.5.2. Sevoflurane
10.5.3. Dexmedetomidine
10.5.4. Desflurane
10.5.5. Remifentanil
10.5.6. Midazolam
10.5.7. Others
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
10.6.1. Intravenous Anesthesia
10.6.2. Inhaled Anesthesia
10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
10.7.1. Hospitals
10.7.2. Ambulatory surgical centers
10.7.3. Specialty clinics
10.8. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2022
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Dashboard
11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. Baxter International Inc.
11.3.1.1. Overview
11.3.1.2. Segments and Product
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. AstraZeneca
11.3.2.1. Overview
11.3.2.2. Segments and Product
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. AbbVie Inc.
11.3.3.1. Overview
11.3.3.2. Segments and Product
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. B. Braun Melsungen AG
11.3.4.1. Overview
11.3.4.2. Segments and Product
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Fresenius SE & Co. KgaA
11.3.5.1. Overview
11.3.5.2. Segments and Product
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Pfizer
11.3.6.1. Overview
11.3.6.2. Segments and Product
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. Hospira Inc.
11.3.7.1. Overview
11.3.7.2. Segments and Product
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. Aspen Pharmacare Holdings Limited
11.3.8.1. Overview
11.3.8.2. Segments and Product
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Hikama Pharmaceuticals plc
11.3.9.1. Overview
11.3.9.2. Segments and Product
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. Abbott Laboratories
11.3.10.1. Overview
11.3.10.2. Segments and Product
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
11.3.11. Avet Pharmaceuticals, Inc
11.3.11.1. Overview
11.3.11.2. Segments and Product
11.3.11.3. Key Financials
11.3.11.4. Market Developments
11.3.11.5. Market Strategy
11.3.12. Piramal Enterprises Limited
11.3.12.1. Overview
11.3.12.2. Segments and Product
11.3.12.3. Key Financials
11.3.12.4. Market Developments
11.3.12.5. Market Strategy
11.3.13. Par Pharmaceutical
11.3.13.1. Overview
11.3.13.2. Segments and Product
11.3.13.3. Key Financials
11.3.13.4. Market Developments
11.3.13.5. Market Strategy
11.3.14. Teva Pharmaceuticals
11.3.14.1. Overview
11.3.14.2. Segments and Product
11.3.14.3. Key Financials
11.3.14.4. Market Developments
11.3.14.5. Market Strategy
11.3.15. Viatris/Mylan
11.3.15.1. Overview
11.3.15.2. Segments and Product
11.3.15.3. Key Financials
11.3.15.4. Market Developments
11.3.15.5. Market Strategy
11.3.16. Novartis AG
11.3.16.1. Overview
11.3.16.2. Segments and Product
11.3.16.3. Key Financials
11.3.16.4. Market Developments
11.3.16.5. Market Strategy
11.3.17. GlaxoSmithKline plc
11.3.17.1. Overview
11.3.17.2. Segments and Product
11.3.17.3. Key Financials
11.3.17.4. Market Developments
11.3.17.5. Market Strategy
11.3.18. Gilead Sciences, Inc.
11.3.18.1. Overview
11.3.18.2. Segments and Product
11.3.18.3. Key Financials
11.3.18.4. Market Developments
11.3.18.5. Market Strategy
11.3.19. Sanofi
11.3.19.1. Overview
11.3.19.2. Segments and Product
11.3.19.3. Key Financials
11.3.19.4. Market Developments
11.3.19.5. Market Strategy
11.3.20. Akorn
11.3.20.1. Overview
11.3.20.2. Segments and Product
11.3.20.3. Key Financials
11.3.20.4. Market Developments
11.3.20.5. Market Strategy
11.3.21. Apotex
11.3.21.1. Overview
11.3.21.2. Segments and Product
11.3.21.3. Key Financials
11.3.21.4. Market Developments
11.3.21.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
